Adults with a mental illness experienced weight loss and glycemic benefits with use of a GLP-1 without worsening of mental ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...

American Medical Association named John J. Whyte, MD, MPH as its next CEO and EVP, effective July 1. Centivo hired Sarah ...

Healthcare Opportunities Fund seems to offer a solid balance of capital stability and income. Read why THQ CEF is a Hold.

Some of it is in the new Boston home of Eli Lilly & Co ., a $700 million research and development facility along Fort Point ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

Roche is among several drugmakers to announce large-scale U.S. investments in response to Trump's push to onshore ...

During a live event, Shuo Ma, MD, PhD, discussed the resistance mutation analysis of patients who had disease progression ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

Hospital nurses immediately diagnosed Kelly with type 1 diabetes, a non-communicable disease (NCD), and put her on a treatment regimen that she will likely need to follow for the rest of her life.

“The legacy I hope to build is one of freedom—freedom from anything that’s keeping you from becoming who you truly want to be in this life. I see so many people stuck in jobs they hate, or just living ...